BioCryst reports Q4 EPS (13c), consensus (6c)

Reports Q4 revenue $131.5M, consensus $130.05M. “We ended 2024 with the strongest execution and performance in the company’s history, and this year is off to a fantastic start, with ORLADEYO revenue already exceeding our initial expectations, the first clinical data from both the BCX17725 and avoralstat programs, and our pediatric label expansion for ORLADEYO anticipated later this year,” said Jon Stonehouse, president and chief executive officer of BioCryst (BCRX).